Protective effect of atorvastatin on bone tissue in orchidectomised male albino Wistar rats.
Recent studies have shown that atorvastatin influences bone metabolism. We investigated its bone protective effect in orchidectomised rats after 12 weeks of treatment. Eight-week-old rats were divided into 3 groups: sham-operated group, control group after orchidectomy and experimental group after orchidectomy with atorvastatin administration (12 mg/kg/day). Bone mineral density and bone marker concentrations of aminoterminal propeptide of procollagen type I (PINP), osteoprotegerin (OPG), insulin-like growth factor 1 (IGF-1) in serum, and carboxy-terminal cross-linking telopeptide of type I collagen (CTX-I), bone alkaline phosphatase (BALP), bone morphogenetic protein 2 (BMP-2) in bone homogenate were measured. Total serum calcium and tibial calcium content was determined. Femurs were used for three-point bending test of the shaft and compression testing of the femoral neck. Bone markers (CTX-I, BALP, BMP-2) in control rats were higher vs. sham-operated rats. Atorvastatin reduced CTX-I, BMP-2 and OPG compared to controls. IGF-1 was decreased in control rats vs. sham-operated rats; atorvastatin increased IGF-1 vs. control rats. Atorvastatin exerts a positive effect on bone metabolism by increasing bone mineral density of the whole body, which had decreased under the effects of orchidectomy. Three-point bending test revealed an increase in maximal load values of the left femurs after atorvastatin administration compared to controls. The diameter of the left femur and length of both femurs were increased after atorvastatin administration compared to controls. Our findings suggest that atorvastatin has a beneficial effect on bone metabolism in orchidectomised rats by decreasing bone turnover, with resulting improvement in bone mineral density and bone biomechanical properties.
Institute of Clinical Biochemistry and Diagnostics, Charles University in Prague, Faculty of Medicine and University Hospital, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. gradosovai@lfhk.cuni.cz
Iveta
I
Gradosova
Helena
H
Zivna
Vladimir
V
Palicka
Sona
S
Hubena
Klara
K
Svejkovska
Pavel
P
Zivny
D000818:Animals; D000069059:Atorvastatin; D015415:Biomarkers / Q000378:metabolism*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000097:blood / Q000378:metabolism; D019245:Compressive Strength / Q000187:drug effects; D004195:Disease Models, Animal; D005269:Femur / Q000187:drug effects / Q000378:metabolism; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D009919:Orchiectomy / Q000009:adverse effects*; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D013977:Tibia / Q000187:drug effects / Q000378:metabolism
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin; D002118:Calcium